您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
HighLife® Transseptal Mitral Valve Replacement (TSMVR) System: Latest Updates Presented at New York Valves 2024, FDA Approved IDE Application to Initiate US Piovtal Study for Treatment of Mitral Regurgitation
2024.06.13
HighLife® Transseptal Mitral Valve Repla···
From June 5 to 7, 2024, the New York Valves (NYV) conference was held, where Prof. Nicolo Piazza of ···
MonarQ™ Transcatheter Tricuspid Valve Replacement (TTVR) Innovative Device: The Latest Results of the FIM Clinical Implantation Were Presented at New York Valves 2024
2024.06.13
MonarQ™ Transcatheter Tricuspid Valve Re···
From June 5 to 7, 2024, the latest results of the FIM clinical implantation of MonarQTM, an innovati···
PEIJIA MEDICAL SHONE AT TWO MAJOR  STRUCTURAL HEART DISEASE  CONGRESSES TO DEMONSTRATE  INNOVATION
2024.04.22
PEIJIA MEDICAL SHONE AT TWO MAJOR STRUC···
On March 18-24 and April 15-20, 2024, Peijia Medical shone at the 5th China Structural Heart Disease···
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SYSTEM APPROVED BY THE NMPA
2024.04.19
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S···
On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by ···
INNOVATIVE TRANSCATHETER EDGETO-EDGE REPAIR (TEER) SYSTEM GeminiOne®: RESULTS OF DMR TREATMENT PUBLISHED FOR THE FIRST TIME
2024.04.15
INNOVATIVE TRANSCATHETER EDGETO-EDGE RE···
On April 12, 2024, the results of GeminiOne® for DMR were published in JACC: Case Reports, a leading···
Trilogy™ THV SYSTEM FOR AR INDICATION: RESULTS FROM ALIGN-AR PIVOTAL TRIAL WERE PUBLISHED IN THE LANCET
2024.03.29
Trilogy™ THV SYSTEM FOR AR INDICATION: R···
On March 26, 2024, the exciting results of JenaValve TrilogyTM System’s pivotal clinical trial, ALIG···
TaurusNXT® NON-GLUTARALDEHYDE CROSSLINKED DRY-TISSUE TAVR SYSTEM COMPLETED ALL PATIENT ENROLLMENT OF ITS PIVOTAL CLINICAL TRIAL
2024.03.01
TaurusNXT® NON-GLUTARALDEHYDE CROSSLINKE···
In February 2024, TaurusNXT® Non-glutaraldehyde Crosslinked dry-tissue TAVR system, a thirdgenerati···
TaurusAtlas Pro, THE SECOND-GENERATION BALLOON DILATATION CATHETER, HAS BEEN APPROVED BY THE NMPA
2024.02.01
TaurusAtlas Pro, THE SECOND-GENERATION B···
The registration application of TaurusAtlas Pro, the second-generation balloon dilatation catheter i···
TaurusTrio AR TAVR SYSTEM COMPLETED ALL PATIENT ENROLLMENT OF ITS MULTI-CENTER PIVOTAL CLINICAL TRIAL
2024.01.29
TaurusTrio AR TAVR SYSTEM COMPLETED ALL ···
In January 2024, TaurusTrio AR TAVR System  successfully completed patient enrollment in its mu···
Academic Conferences at Home and Abroad are in Full Swing, Where Peijia Medical Has  Showcased a Variety of Products and Received Enthusiastic Responses
2023.12.29
Academic Conferences at Home and Abroad ···
❖ TaurusOne® Transcatheter Aortic Valve Replacement (TAVR) System■ Four-Year Clinical Follow-up Resu···
Shanghai Renji Hospital Completed the First Patient Enrollment of the Registration Clinical  Trial of Achieva’s CereStellar™ Intracranial Assist Stent
2023.12.22
Shanghai Renji Hospital Completed the Fi···
Achieva Medical initiated a prospective, multi-center, randomized-controlled clinical trial to evalu···
Prof. Yu Bo's Team at the Second Affiliated Hospital of Harbin Medical University  Successfully Completed the First Enrollment at the Chinese Clinical Trial Center for Peijia  HighLife® Trans-septal Mitral Valve Replacement (TSMVR) System
2023.11.01
Prof. Yu Bo's Team at the Second Affilia···
On October 31, 2023, the team led by Prof. Yu Bo at the Second Affiliated Hospital of Harbin Medical···
Top